Cargando…

Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy

Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Safinejad, Moosareza, Rigi, Amir, Zeraati, Malihe, Heidary, Zohreh, Jahani, Shohreh, Chauhan, Narendra Pal Singh, Sargazi, Ghasem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655864/
https://www.ncbi.nlm.nih.gov/pubmed/36371207
http://dx.doi.org/10.1186/s13065-022-00886-y
_version_ 1784829291560697856
author Safinejad, Moosareza
Rigi, Amir
Zeraati, Malihe
Heidary, Zohreh
Jahani, Shohreh
Chauhan, Narendra Pal Singh
Sargazi, Ghasem
author_facet Safinejad, Moosareza
Rigi, Amir
Zeraati, Malihe
Heidary, Zohreh
Jahani, Shohreh
Chauhan, Narendra Pal Singh
Sargazi, Ghasem
author_sort Safinejad, Moosareza
collection PubMed
description Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid (3,4-DHCA) as a linker. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), nitrogen adsorption–desorption measurements, and X-ray powder diffraction (XRD) have all been used to characterize it thoroughly. The La-based MOF showed good biocompatibility with the human breast cancer cell line MDA-MB-468. The ability of 3,4-DHCA to treat MDA-MB-468 cells was confirmed by 40.35% cell viability with La-based MOF. Based on the findings, La-based MOF can be recommended as a promising candidate for anticancer delivery.
format Online
Article
Text
id pubmed-9655864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96558642022-11-15 Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy Safinejad, Moosareza Rigi, Amir Zeraati, Malihe Heidary, Zohreh Jahani, Shohreh Chauhan, Narendra Pal Singh Sargazi, Ghasem BMC Chem Research Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid (3,4-DHCA) as a linker. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), nitrogen adsorption–desorption measurements, and X-ray powder diffraction (XRD) have all been used to characterize it thoroughly. The La-based MOF showed good biocompatibility with the human breast cancer cell line MDA-MB-468. The ability of 3,4-DHCA to treat MDA-MB-468 cells was confirmed by 40.35% cell viability with La-based MOF. Based on the findings, La-based MOF can be recommended as a promising candidate for anticancer delivery. Springer International Publishing 2022-11-12 /pmc/articles/PMC9655864/ /pubmed/36371207 http://dx.doi.org/10.1186/s13065-022-00886-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Safinejad, Moosareza
Rigi, Amir
Zeraati, Malihe
Heidary, Zohreh
Jahani, Shohreh
Chauhan, Narendra Pal Singh
Sargazi, Ghasem
Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title_full Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title_fullStr Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title_full_unstemmed Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title_short Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
title_sort lanthanum-based metal organic framework (la-mof) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655864/
https://www.ncbi.nlm.nih.gov/pubmed/36371207
http://dx.doi.org/10.1186/s13065-022-00886-y
work_keys_str_mv AT safinejadmoosareza lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT rigiamir lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT zeraatimalihe lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT heidaryzohreh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT jahanishohreh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT chauhannarendrapalsingh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy
AT sargazighasem lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy